Table 2 Serum HE4 and CA125 concentrations in patients with endometriosis, endometrial, and ovarian cancer

From: Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts

   HE4 (pM) CA125 (U ml−1)
Diagnosis n Mean s.d. Median (range) P -value a Mean s.d. Median (range) P -value a
Controls 66 40.5 10.3 38.6 (27.0–80.7) 8.9 6.2 6.7 (2.2–31.2)
Endometriosis all 129 45.5 13.4 43.5 (15.2–111.0) 35.8 36.0 25.3 (0.8–182.0)
 Stage 1 16 46.7 11.4 42.9 (35.1–80.9) 0.96192 15.6 9.8 11.5 (5.1–44.4) 0.34560
 Stage 2 17 44.9 13.1 43.9 (28.7–72.0) 0.99718 21.4 18.4 14.8 (3.5–70.5) 0.09637
 Stage 3 33 43.2 11.4 43.4 (15.2–68.0) 25.1 22.7 14.8 (0.9–79.0)
 Stage 3 w/o OvEndo 9 43.9 10.1 43.8 (32.6–61.9) 0.99971 23.3 25.4 13.4 (2.6–79.0) 0.58802
 Stage 4 63 46.5 15.0 44.0 (26.8–111.0) 50.4 43.1 36.7 (0.8–182.0)
 Stage 4 w/o OvEndo 18 43.5 12.1 40.9 (27.4–64.5) 0.99973 40.8 30.9 32.1 (0.8–127.0) 0.00001
 Ovarian endometriosis 69 46.0 14.9 44.0 (15.2–111.0) 0.89441 44.3 42.1 33.7 (0.9–182.0) 0.00000
Endometrial cancer 16 99.2 76.4 73.3 (26.5–330.5) 0.00001 22.0 23.0 15.5 (9.6–106.0) 0.02915
Ovarian cancer 14 1125.4 2670.0 268.3 (46.5–10250.0) 0.00000 1117.1 1971.0 240.0 (6.6–6890.0) 0.00000
       0.00000b      0.00000b
 Serous 7 2031.1 3669.1 562.5 (46.5–10250.0) 1938.7 2588.7 341.0 (28.9–6890.0)
 Mucinous 3 202.6 189.7 113.0 (74.4–420.5) 201.5 186.0 221.0 (6.6–377.0)
 Clear cell 2 397.6 477.2 397.6 (60.1–735.0) 674.5 587.6 674.5 (259.0–1090.0)
 Endometrioid 1 70.0 70.0 97.0 97.0
 Small cell 1 64.1 64.1 17.8 17.8
  1. a Tukey's multiple comparisons of means, in comparison to the healthy controls.
  2. b Comparison to patients with ovarian endometriosis.